Type 2 Diabetes Mellitus
Conditions
Brief summary
The Impact of Metformin and Dipeptidyl Peptidase- 4 Inhibitors on Cognitive Function and cardiovascular protection in Type 2 Diabetic Patients
Detailed description
This study aims to investigate the effect of daily oral DPP4 inhibitors and oral metformin on neurodegeneration in type 2 diabetic patients. This study aims to compare between the cardiovascular protective properties of DPP-4 inhibitors and Metformin in type 2 diabetic patients.
Interventions
DRUGVildagliptin
observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients
Sponsors
National Institute of Diabetes and Endocrinology, Egypt
MTI University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patient should be diagnosed with Type 2 diabetes mellitus (T2DM) and guided with HA1c ≥7, age ≥40 years. * moderate hypertension.
Exclusion criteria
* • Diabetic patients who have been currently receiving anti-diabetic agents other than metformin and/or insulin * Patients with type 1 DM, active liver disease, recent history of cardiovascular disease (acute coronary syndrome, coronary artery intervention, New York Heart Association Class III/IV heart failure, stroke, transient ischemic neurologic event, or new/worsening symptoms of coronary heart disease or cerebrovascular disease), severe peripheral vascular disease, triglyceride levels ≥ 600 mg/dL, history of HIV infection, pancreatitis, malignancy or clinically important hematologic disorder, and an estimated glomerular filtration rate (eGFR; calculated using the Modification of Diet in Renal Disease formula) less than 30 mL/min/1.73 m2. * Moreover, patients with dementia, AD, those were in delirium status during evaluation period, patients with psychotic disease (schizoaffective disorder, etc.) * Alcohol and substance addiction were not enrolled in the study. * Also, patients who have any hypersensitivity to metformin or to DPP4 inhibitors were also excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| improve the neurodegeneration and cardiovascular effect in diabetic patients | September 2022 | improve the cognition and cardiovascular effect in type 2 diabetic patients |
Countries
Egypt
Contacts
Primary ContactToka H Elemary
Backup ContactDalia Zaafar
Outcome results
None listed